BioSpace News Archive

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it int

-- In a Randomized Investigator Sponsored Study, XPOVIO in Combination with Standard Induction and Consolidation Chemotherapy Demonstrated Improved Survival in Older, Fit Patients with Acute Myeloid Leukemia - -- Company to Host Virtual Investor and Analyst Event on Tuesday, December 8th at 1:00 PM ET to Review Highlights from the Data Presented at ASH 2020 --

Achieve Life Sciences, Inc. announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Marinus. Marinus has granted the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offer

Champions Oncology, Inc., a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced it will report its financial and operational results for the second quarter ended October 31, 2020, on Monday, December 14, 2020, after market close.

Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Drew Davies, Executive Vice President and Chief Financial Officer will present at the 13 th Annual LD Micro Conference. Mr. Davies is scheduled to present on Monday, December 14 th at 12:40

Lannett Company, Inc. announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. In connection with the pro

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that clinical proof-of-concept in patients with sickle cell disease (SCD) has been observed in the ongoing randomized, placebo-controlled, multi-center Phase 1 trial of FT-4202.